Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: SEC Rule changes

The cynic in me can't help wondering if the predictable favorable updates about PDSG, the '336, and the proposed Rule changes by the SEC, played a contributory factor in the surge in applicants for a BoD seat.

Unless there are no new licensees, nor sales by PDSG, the share price has a good probability of increasing during the next twelve months, and as such wouldn't this render moot the "increasing shareholder value" platform?

Thoughts and comments more than welcome.

.

.

.

Be well

Share
New Message
Please login to post a reply